The synergistic effect of cabozantinib and EGFR-specific CAR-NK-92 cells was studied in vitro and in vivo, and the CAR-NK-92 cells could lyse RCC cells in an EGFR-specific manner. The gene discussed is EGFR; the disease is renal cell carcinoma.